iOnctura SA

ACTIVE

Campus Biotech Innovation Park, Genève, Switzerlandwww.ionctura.comHolding11–50 employeesEstablished: 2017-06-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 2

50.0%

Trial Status Distribution

Active, not recruiting

16.7%

Recruiting

83.3%

Clinical Trials

Trials sponsored by this organization (6)

A study to investigate the effects of IOA-244 in healthy volunteers, including assessment of food effect

Phase 1

Active, not recruiting

interventional

Aug 202432 participants

First-in-Human Dose Study of IOA-244 in patients with advanced or metastatic cancers.

Phase 1

Recruiting

34 participants

Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel

A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01)

Phase 2

Recruiting

45 participants

Phase II study of Roginolisib in UM patients

Phase 2

Recruiting

43 participants

A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)

Phase 2

Recruiting

27 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations